SERA.US Sera Prognostics Inc

Healthcare Biotechnology USA Stocks
2.05 USD
Close of Nov 18, 2026
1.56 3.85
Market cap
USD 79.5M
P/E
-
P/B
1.46x
ROE
-65.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SERA.US undervalued?

Graham number

The Graham number of Sera Prognostics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sera Prognostics Inc fundamental analysis

No fundamental analysis for Sera Prognostics Inc yet.

Sera Prognostics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sera Prognostics Inc

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services…

Full company profile